AWH Stock Overview
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Aspira Women's Health Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.07 |
| 52 Week High | US$6.75 |
| 52 Week Low | US$2.31 |
| Beta | 1.61 |
| 1 Month Change | -0.97% |
| 3 Month Change | -36.17% |
| 1 Year Change | -20.36% |
| 3 Year Change | -95.78% |
| 5 Year Change | -83.36% |
| Change since IPO | -99.94% |
Recent News & Updates
Recent updates
Aspira Women’s Health slips 23% on common stock offering
Aug 22Aspira Women’s Health GAAP EPS of -$0.07 in-line, revenue of $2.06M misses by $0.34M
Aug 10Is Aspira Women's Health (NASDAQ:AWH) Using Too Much Debt?
Aug 02
Is Aspira Women's Health (NASDAQ:AWH) Weighed On By Its Debt Load?
Apr 11Health Check: How Prudently Does Aspira Women's Health (NASDAQ:AWH) Use Debt?
Jan 07Aspira Women's Health (NASDAQ:AWH) Has Debt But No Earnings; Should You Worry?
Sep 24Aspira Women's Health Inc.'s (NASDAQ:AWH) Intrinsic Value Is Potentially 69% Above Its Share Price
Jul 06This Is Why Aspira Women's Health Inc.'s (NASDAQ:AWH) CEO Can Expect A Bump Up In Their Pay Packet
Jun 15Does Aspira Women's Health (NASDAQ:AWH) Have A Healthy Balance Sheet?
May 19A Look At The Fair Value Of Aspira Women's Health Inc. (NASDAQ:AWH)
Mar 28Shareholder Returns
| AWH | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -4.5% | 1.2% | 2.7% |
| 1Y | -20.4% | -0.05% | 26.0% |
Return vs Industry: AWH underperformed the US Medical Equipment industry which returned -1.9% over the past year.
Return vs Market: AWH underperformed the US Market which returned 25% over the past year.
Price Volatility
| AWH volatility | |
|---|---|
| AWH Average Weekly Movement | 8.1% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AWH's share price has been volatile over the past 3 months.
Volatility Over Time: AWH's weekly volatility has decreased from 14% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 64 | Nicole Sandford | aspirawh.com |
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company’s products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1’s high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis.
Aspira Women's Health Inc. Fundamentals Summary
| AWH fundamental statistics | |
|---|---|
| Market cap | US$36.80m |
| Earnings (TTM) | -US$16.69m |
| Revenue (TTM) | US$9.15m |
4.1x
P/S Ratio-2.3x
P/E RatioIs AWH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AWH income statement (TTM) | |
|---|---|
| Revenue | US$9.15m |
| Cost of Revenue | US$3.89m |
| Gross Profit | US$5.26m |
| Other Expenses | US$21.95m |
| Earnings | -US$16.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -1.35 |
| Gross Margin | 57.48% |
| Net Profit Margin | -182.32% |
| Debt/Equity Ratio | -95.8% |
How did AWH perform over the long term?
See historical performance and comparison